T. Rowe Price ( TROW) estimates, target boosted at Barclays. TROW estimates increased through 2010. Company continues to attract steady inflows. Equal-weight rating and new $47 price target. T. Rowe Price ( TROW) upgraded at Friedman, Billings Ramsey from Underperform to Market Perform. $42 price target. Fund performance has turned around, and the company has kept a tight lid on costs. UnitedHealth Group ( UNH) upgraded at Credit Suisse to Outperform from Neutral. Cites improving fundamentals and a better outlook as the co. is positioned best to capitalize on growth opportunities from the healthcare reform. Increased price target to $33 from $27.
Eastman Chemical ( EMN) numbers raised at Merrill/BofA to $52. Estimates also increased, to reflect higher operating margins. Neutral rating. Ingersoll-Rand ( IR) numbers raised at Goldman to $26 from $24. Downside concerns have been reduced due to its outperformance in cost cutting initiatives, Trane synergies, and productivity. Maintained Neutral rating. Ingersoll-Rand ( IR) numbers raised at Barclays to $30. Estimates also boosted, to reflect a sharp margin recovery. Equal-weight rating. Ingersoll-Rand ( IR) numbers raised at Morgan Stanley. Price target raised to $24 from $23. 2009 EPS estimates raised to $1.37 from $1.08. Ingersoll-Rand ( IR) numbers raised at UBS. Price target raised to $28 from $21. 2009 EPS estimates raised to $1.60 from $1.30. Maintains Neutral rating. Laboratory Corp. of America ( LH) target raised at Goldman to $70 from $64 based on improving volume trends and a return to historical pricing strategies. Maintained Neutral rating. LSI Corp ( LSI) numbers raised at Goldman to $5 from $4. Long term valuation looks attractive as the co. continues to increase its traction with new products which suggests a robust full-cycle profitability trend. Maintained Neutral rating. Northrop Grumman ( NOC) target lowered at Credit Suisse to $57 from $53 given the co.'s lower visibility and unpredictable earnings stream. Maintained Neutral rating. Sepracor ( SEPR) estimates, target raised at UBS. SEPR estimates increased through 2010. Company seeing higher product sales and costs are falling. Neutral rating and new $16.50 price target. Sappi ( SPP) target lowered at Credit Suisse to $2.50 from $3.10. Market estimates have noticeable downside risk reflecting rising future interest costs, a weaker than expected Q3, and a further than expected sequential weakening of results in Q4 due to falling prices and weakening demand. Maintained Underperform rating. Walter Energy ( WLT) numbers increased at Friedman, Billings Ramsey. Shares of WLT now seen reaching $59. Estimates also boosted, to reflect lower costs. Outperform rating.